From cell surface to nucleus: CCRL2 regulates response to hypomethylating agents in myelodysplastic syndromes

Haematologica. 2023 Jul 1;108(7):1729-1730. doi: 10.3324/haematol.2022.282477.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Azacitidine / pharmacology
  • Azacitidine / therapeutic use
  • Cell Nucleus
  • DNA Methylation
  • Humans
  • Myelodysplastic Syndromes* / drug therapy
  • Myelodysplastic Syndromes* / genetics

Substances

  • Azacitidine